- Home
- CHRS vs SFWL Comparison
CHRS vs SFWL Comparison
Compare CHRS & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SFWL
- Stock Information
- Founded
- CHRS 2010
- SFWL 2001
- Country
- CHRS United States
- SFWL China
- Employees
- CHRS 177
- SFWL N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SFWL Trucking Freight/Courier Services
- Sector
- CHRS Health Care
- SFWL Industrials
- Exchange
- CHRS Nasdaq
- SFWL Nasdaq
- Market Cap
- CHRS 149.9M
- SFWL 82.3M
- IPO Year
- CHRS 2014
- SFWL 2023
- Fundamental
- Price
- CHRS $1.37
- SFWL $1.04
- Analyst Decision
- CHRS Strong Buy
- SFWL
- Analyst Count
- CHRS 4
- SFWL 0
- Target Price
- CHRS $4.51
- SFWL N/A
- AVG Volume (30 Days)
- CHRS 1.4M
- SFWL 23.3K
- Earning Date
- CHRS 11-05-2025
- SFWL 08-27-2025
- Dividend Yield
- CHRS N/A
- SFWL N/A
- EPS Growth
- CHRS N/A
- SFWL 31.68
- EPS
- CHRS 1.55
- SFWL 0.14
- Revenue
- CHRS $272,209,000.00
- SFWL $540,461,000.00
- Revenue This Year
- CHRS N/A
- SFWL N/A
- Revenue Next Year
- CHRS $126.00
- SFWL N/A
- P/E Ratio
- CHRS $0.88
- SFWL $7.40
- Revenue Growth
- CHRS 52.33
- SFWL 21.10
- 52 Week Low
- CHRS $0.66
- SFWL $0.86
- 52 Week High
- CHRS $2.43
- SFWL $1.60
- Technical
- Relative Strength Index (RSI)
- CHRS 73.83
- SFWL 49.67
- Support Level
- CHRS $1.26
- SFWL $1.00
- Resistance Level
- CHRS $1.39
- SFWL $1.14
- Average True Range (ATR)
- CHRS 0.08
- SFWL 0.08
- MACD
- CHRS 0.02
- SFWL -0.00
- Stochastic Oscillator
- CHRS 94.10
- SFWL 13.79
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.